Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology company developing diffusing alpha-emitters radiation therapy (Alpha-DaRT), a targeted radiation treatment platform designed to address solid tumors. The technology delivers alpha particles directly to cancer cells, with the company currently advancing multiple clinical trials across cancer types including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Additional preclinical and pending clinical programs address brain cancer and other malignancies.

The company operates primarily as a research and development enterprise, with no approved commercial products currently generating revenue. Its business model centers on advancing Alpha-DaRT through clinical development stages while building intellectual property around the therapeutic platform. Alpha Tau Medical maintains its operations in Jerusalem, Israel, where it was incorporated, with a workforce of approximately 125 full-time employees supporting its development pipeline and regulatory activities.

The company is listed on Nasdaq and maintains a market capitalization of approximately $0.7 billion. As a clinical-stage entity, Alpha Tau Medical's financial structure reflects typical biotechnology capital requirements, with operations funded through equity markets and potential partnership or licensing arrangements rather than product revenues.